REVBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 23:56):

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics...

Stats
本日の出来高	5 474.00
平均出来高	319 103
時価総額	3.52M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-5.39 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.06
ATR14	$0.0400 (1.86%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Tidmarsh George F	Sell	27 771	Common Stock
2023-10-16	Tidmarsh George F	Sell	1 845	Common Stock
2023-10-16	Tidmarsh George F	Sell	10 957	Common Stock
2023-09-27	Chawla Lakhmir S	Buy	0
2023-09-28	Tidmarsh George F	Sell	1 429	Common Stock

INSIDER POWER
-12.53
Last 48 transactions
Buy: 316 523 \| Sell: 2 020 596

ボリューム相関

長: 0.03 (neutral)

短: 0.25 (neutral)

Signal:(47.821) Neutral

Revelation Biosciences, 相関

10 最も正の相関
CNSL	0.915
EYE	0.915
AHCO	0.912
CCSI	0.905
DISH	0.879
COLB	0.878
ALHC	0.875
GBNH	0.872
CPTN	0.868
CSSE	0.864

10 最も負の相関
KTCC	-0.913
JBSS	-0.895
RKDA	-0.883
HCDI	-0.882
HTBI	-0.874
WINT	-0.874
MBIN	-0.867
HUBG	-0.867
PESI	-0.861
WIRE	-0.859

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Revelation Biosciences, 相関 - 通貨/商品

0.38
( neutral )

0.69
( moderate )

0.00
( neutral )

0.11
( neutral )

0.67
( moderate )

Revelation Biosciences, 財務諸表

Annual	2023
収益:	$0
総利益:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2023
収益:	$0
総利益:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2022
収益:	$0
総利益:	$-40 008.00 (0.00 %)
EPS:	$-600.77

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.310

Financial Reports:

No articles found.

Revelation Biosciences,

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.